Guerbet (XPAR:GBT) Marketable Securities: €28.3 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:GBT Guerbet SA XPAR:GBT
69 GF Score
Price €8.89
GF Value €19.55
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Guerbet Marketable Securities?

Guerbet XPAR:GBT +0.68% 69 Marketable Securities is €28.3 Mil as of Dec. 2025. GuruFocus rates XPAR:GBT with a GF Score™ of 69/100 and a GF Value™ of €19.55 (Possible Value Trap). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Guerbet's Marketable Securities for the quarter that ended in Dec. 2025 was €28.3 Mil.

Guerbet's annual Marketable Securities declined from Dec. 2023 (€41.5 Mil) to Dec. 2024 (€36.2 Mil) and declined from Dec. 2024 (€36.2 Mil) to Dec. 2025 (€28.3 Mil).

Guerbet  (XPAR:GBT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Guerbet Marketable Securities Related Terms

Guerbet Marketable Securities Historical Data

* Premium members only.

The historical data trend for Guerbet's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guerbet Marketable Securities Chart

Guerbet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.90 41.17 41.48 36.17 28.33

Guerbet Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.48 56.62 36.17 53.05 28.33
XPAR:GBT
69GF Score
Guerbet SA XPAR:GBT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guerbet Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €28.3 Mil mean?
Guerbet (XPAR:GBT) has a Marketable Securities of €28.3 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Guerbet and its competitors.
Is Guerbet's Marketable Securities too high?
Guerbet's current Marketable Securities is €28.3 Mil. Overall, Guerbet has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Guerbet's Marketable Securities compare to ABT and SYK?
Guerbet's Marketable Securities of €28.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Guerbet and its competitors. Guerbet's current Marketable Securities is €28.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guerbet stock overvalued right now?
Based on GuruFocus' analysis, Guerbet (XPAR:GBT) is currently considered Possible Value Trap. The stock's GF Value™ is €19.55, compared to a current price of €8.89 — trading 54.5% below its estimated fair value. The current Marketable Securities is €28.3 Mil. Guerbet's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Guerbet (XPAR:GBT), the current Marketable Securities is €28.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guerbet (XPAR:GBT) Overvalued in 2026?

Based on GuruFocus' analysis, Guerbet stock appears to be undervalued. The current stock price of €8.89 is trading 54.5% below its estimated GF Value™ of €19.55. GuruFocus considers Guerbet to be Possible Value Trap.

Key valuation signals for XPAR:GBT:

  • Marketable Securities: €28.3 Mil
  • GF Value™: €19.55 vs. price of €8.89 (54.5% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the XPAR:GBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guerbet Business Description

Other Exchanges 0ELV:UK4G8:Germany
Address 15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
69GF Score

Get the complete analysis for XPAR:GBT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.89
Price
€19.55
GF Value